Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Atorvastatin is one of a group of statins widely used to treat heart and blood vessel diseases. The medication works by lowering cholesterol in the blood. This new study shows that atorvastatin influences the way people experience certain emotions, giving us important insights about disorders such as anxiety and depression.

The collage of faces of surprised people on coloured backgrounds.

This experimental medicine trial investigated the effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers.

Participants took atorvastatin for seven days and they were subsequently more likely to identify faces showing fearful emotions. 

The study results reveal for the first time the early influence of atorvastatin on emotional recognition of fear - something that is linked to anxiety and depression, as well as the effects of commonly-used antidepressants on these conditions.

Dr Riccardo De Giorgi, study author and Wellcome Trust Doctoral Training Fellow, University of Oxford, said:

 

'Our findings are important because they show for the first time that a very commonly prescribed medication, atorvastatin, can affect the way we perceive certain emotions. This is relevant to further studies investigating whether statins could be used for treating depressive and anxiety disorders.'

Read the full study, The effects of atorvastatin on emotional processing, reward learning, verbal memory and inflammation in healthy volunteers: An experimental medicine study, in the Journal of Psychopharmacology 

NIHR OXFORD HEALTH BIOMEDICAL RESEARCH CENTRE NEWS

Please follow the link below to read the news on the NIHR BRC website.

Similar stories

Tackling Suicide Risk in People With Mental Disorders

Clinical researchers from Oxford University’s Department of Psychiatry and Oxford Health NHS Foundation Trust, together with colleagues from elsewhere, have developed guidance to help clinicians identify and treat patients at risk of suicide.

Alcohol affects the Human Biological Clock

The short-term effects of excessive drinking are well known, but to date it has been less certain whether alcohol also accelerates the aging process.

New Meta-Analysis Highlights No Antidepressant Effect of Statins Administered in Monotherapy

This new systematic review and meta-analysis of randomised controlled trials assesses the effects of statins given alone, without concomitant antidepressant treatment, in people with depressive symptoms, but who do not have a formal diagnosis of a depressive disorder.

New Oxford Study Evaluates Pharmacological Treatment for Insomnia

Two drugs, eszopiclone and lemborexant – both not currently licenced for the treatment of insomnia in the UK – were shown to perform better than others, both in the acute and long-term treatment of insomnia in adults, according to a new Oxford study exploring the pharmacological management of insomnia.

Moderate Drinking Linked to Brain Iron and Cognitive Decline

Consumption of seven or more units of alcohol per week is associated with higher iron levels in the brain. Iron accumulation in the brain has been linked with Alzheimer's and Parkinson's diseases and is a potential mechanism for alcohol-related cognitive decline.